Novel pediatric delivery systems for second-line anti-tuberculosis medications: A case study

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 9, 2013, Pages 1239-1241

  Furin, J ^a   Brigden, G ^b   Lessem, E ^c   Becerra, M C ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c Treatment Action Group   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

MDR TB; PAS; Pediatric; TB

Indexed keywords

AMINOSALICYLIC ACID; ISONIAZID; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACCURACY; ARTICLE; CHILD; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG USE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PEDIATRIC DELIVERY SYSTEM; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; TUBERCULOSIS;

EID: 84883041248     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0196     Document Type: Article

References (9)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
2. Zignol M, van Gemert W, Falzon D, et al. Surveillance of antituberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119D.
3. Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis 2010; 50 (Suppl 3): S184-S194.
4. Ettehad D, Schaaf H S, Seddon J A, Cooke G S, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 449-456.
5. Al-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. Pediatr Infect Dis 2011; 30: 501-505.
6. Reubenson G. Pediatric drug-resistant tuberculosis: a global perspective. Paediatr Drugs 2011; 13: 349-355.
7. Mendez Echevarria A, Baquero Artigao F, Garcia Miguel M J, et al. Multidrug-resistant tuberculosis in the pediatric age group. An Pediatr (Barc) 2007; 67: 206-211.
8. Peacock-Villada E, Richardson B A, John-Stewart G C. Post-HAART outcomes in pediatric populations: comparison of r esource-limited and developed countries. Pediatrics 2011; 127: e423-441.
9. Peloquin C A, Berning S E, Huitt G A, Childs J M, Singleton M D, James G T. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999; 159: 932-934.